Gastrointestinal Agents : Agents Used in Peptic Ulcer Disease : H2 Receptor Antagonists
IFADI1 “Fadin lyo injection” 20 mg/vial
IFAMO1 “Famodine injection” 20 mg/ml; 2 ml/amp
OFAMO1 “Famotidine F.C.tablet” 20 mg/tab
OULST2 “Ulstop F.C.tablet” 20 mg/tab
適應症：
IFADI1, IFAMO1：住院病人伴隨有病理性胃酸分泌過高之症狀，頑固性（難治的）十二指腸潰瘍，或不能口服之病人消化性潰瘍之短期替代療法。
OFAMO1, OULST2：胃潰瘍、十二指腸潰瘍、吻合部潰瘍、上部消化管出血（消化性潰瘍、急性stress潰瘍、出血性胃炎而引起的）逆流性食道炎、Zollinger-ellison症候群。
Usual dose:
Duodenal ulcer, Gastric ulcer: PO/IV
Adult: PO 20 bid or 40 mg hs, IV 20 mg q12h; maintenence 20 mg hs.
Pediatric (> 1 yr): 0.25-0.5 mg/kg/day IV; 0.5 mg/kg/day PO hs or bid, max. 40 mg/day.
GERD: PO/IV
Adult: 20 mg PO bid for up to 6 wks; 20 mg IV q12h.
Pediatric (> 1 yr): 0.25-0.5 mg/kg/day IV, max. 40 mg/day; 1 mg/kg/day PO divided twice daily up to 40 mg twice daily; max. 80 mg/day; duration based upon response.
Gastric hypersecretion: PO/IV
Adult: 20-160 mg PO q6h; IV 20 mg q12h.
Dose adjustment:
Renal impairment:
Adult: CrCl < 50 ml/min, 50% of dose or increase dosing interval to 36-48 h.
Pediatric: CrCl 30-60 ml/min/1.48 m2, give 50% of dose; CrCl < 30 ml/min/1.48 m2 dosing, give 25% of dose.
Adverse effect:
Common: constipation, diarrhea, dizziness.
Serious: Stevens-Johnson syndrome, toxic epidermal necrolysis, necrotizing enterocolitis in fetus or newborn; increased liver enzymes, seizure, interstitial pneumonia.
健保使用規範：同aluzaine。